Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice

Chemical Research in Toxicology

Volumn 11, Issue 4, 1998, Pages 252-259

  He, Kan ^a   Iyer, Krishna R ^b   Hayes, Roger N ^b   Sinz, Michael W ^b   Woolf, Thomas F ^b   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; BERGAMOTTIN; CYTOCHROME P450; FUROCOUMARIN; LIVER ENZYME; STEROID MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG BIOAVAILABILITY; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME KINETICS; ENZYME MODIFICATION; ENZYME PURIFICATION; EQUILIBRIUM CONSTANT; FRUIT JUICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PROTEIN EXPRESSION; TESTOSTERONE METABOLISM;

BEVERAGES; CITRUS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MIXED FUNCTION OXYGENASES; PSORALENS;

CITRUS X PARADISI;

EID: 0031947562     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx970192k     Document Type: Article

References (47)

1. Bailey, D. G., Spence, J. D., Munoz, C., and Arnold, J. M. O. (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337, 268-269.
2. Bailey, D. G., Arnold, J. M. O., Bend, J. R., Tran, L. T., and Spence, J. D. (1995) Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br. J. Clin. Pharmacol. 40, 135-140.
3. Ducharme, M. P., Warbasse, L. H., and Edwards, D. J. (1995) Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol Ther, 57, 485-491.
4. Kuferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J., and Krahenbuhl, S. (1995) Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58, 20-28.
5. Hukkinen, S. K., Varhe, A., Olkkola, K. T., and Neuvonen, P. J. (1995) Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther. 58, 127-131.
6. Benton, R. E., Hoig, P. K., Zamaani, K., Cantilena, L. R., and Woosley, R. L. (1996) Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of re polarization on the electrocardiogram. Clin. Pharmacol. Ther. 59, 383-388.
7. Weber, A., Jager, R., Borner, A., Klinger, G., Vollanth, R., Mathey, K., and Balogh, A. (1996) Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 53, 41-7.
8. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. (1994) Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-422.
9. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., and Guzelian, P. S. (1987) Identification of glucocorticoid-inducible cytochrome P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80, 1029-1036.
10. Lown, K. S., Bailey, D. G., Fontana, R. J., Janardan, S. K., Adair, C. H., Fortlage, L. A., Brown, M. B., Guo, W., and Watkins, P. B. (1997) Grapefruit juice increases felodipine oral bioavailability in humans by decreasing intestinal CYP 3A protein expression. J. Clin. Invest. 99, 1-9.
11. Correia, M. A., Davoll, S. H., Wrighton, S. A., and Thomas, P. E. (1992) Degradation of rat liver cytochrome P450 3A after their inactivation by 3, 5-dicarbethoxy-2, 6-dimethyl-4-ethyl-l,4-dihydro-pyridine: characterization of the proteolytic system. Arch. Biochem. Biophys. 297, 228-238.
12. Miniscalco, A., Lundahl, J., Regardh, C. G., Edgar, B., and Eriksson, U. G. (1992) Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol, Exp. Ther. 261, 1195-1199.
13. Ghosal, A., Satoh, H., Thomas, P. E., Bush, E., and Moore, D. (1996) Inhibition and kinetics of cytochrome P450 3A4 activity in microsomes from rat, human and cDNA-expressed human cytochrome P450. Drug Metab. Dispos. 24, 940-947.
14. Bailey, D. G., Arnold, J. M. O., Munoz, C., and Spence, J. D. (1993) Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. PharmacoL Ther. 53, 637-642.
15. Rashid, J., McKinstry, C., Renwick, A. G., Dirnhuber, M., Waller, D. G., and George, C. F. (1993) Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br. J. Clin. Pharmacol. 36, 460-463.
16. Edwards, D. J., Bellevue, F. H., III, and Woster, P. M. (1996) Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos. 24, 1287-1290.
17. Bellevue, F. H., Woster, P. M., Edwards, D. J., He, K., and Hollenberg, P. F. (1997) Synthesis and biological evaluation of 6',7'-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450 3A4. Bioorg. Med. Chem. Lett. 7 2593-2598.
18. Schmiedlin-Ren, P., Edwards, D. J., Fitzsimmons, M. E., He, K., Lown, K. S., Woster, P. M., Rahman, A., Thummel, K. E., Fisher, J. M., Hollenberg, P. F., and Watkins, P. B. (1997) Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents - decreased enterocyte CYP 3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25, 1228-1233.
19. Labbe, G., Descatiore, V., Beaune, P., Letteron, P., Larrey, D., and Pessayre, D. (1989) Suicide inactivation of cytochrome P-450 by methoxsalen. evidence for the covalent binding of a reactive intermediate to the protein moiety. J. Pharmacol. Exp. Ther. 250, 1034-1042.
20. Cai, Y., Baer-Dubowska, W., Ashwood-Smith, M. J., Ceska, O., Tachibana, S., and DiGiovanni, J. (1996) Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem. Res. Toxicol, 9, 729-736.
21. Gillam, E. M., Baba, T., Kim, B. R., Ohmori, S., and Guengerich, F. P. (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coil and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305, 123-131.
22. Strobel, H. W., and Dignam, J. D. (1978) Purification and properties of NADPH-cytochrome P450 reductase. Methods Enzymol. 52, 89-92.
23. Waxman, D. J., and Walsh, C. (1982) Phenobarbital-induced rat liver cytochrome P450. J. Biol. Chem. 257, 10446-10457.
24. Omura, T., and Sato, R. (1964) The carbon-monooxide binding pigment of liver microsomes. J. Biol. Chem. 239, 2370-2378.
25. Belman, S. (1963) The fluorimetric determination of formaldehyde. Anal. Chim. Acta 29, 120-126
26. Roberts, E. S., Hopkins, N. E., Alworth, D. A., and Hollenberg, P. F. (1993) Mechanism-based inactivation of cytochrome P450 2Bl by 2-ethynylnaphthalene: Identification of an active-site peptide. Chem. Res. Toxicol. 6, 470-479.
27. Tassaneeyakul, W., Birkett, D. J., Veronese, M. E., McManus, M. E., Tukey, R. H., Quattrochi, L. C., Gelboin, H. V., and Miners, J. O. (1993) Specificity of substrate and inhibitor probes for human cytochrome P450 1A1 and 1A2. J. Phamacol. Exp. Ther. 265, 401-407.
28. Fentem, J. H., and Fry, J. R. (1992) Metabolism of coumarin by rat, gerbil, and human liver microsomes. Xenobiotica 22, 357-367.
29. Miners, J. O., Smith, K. J., Robson, R. A., McManus, M. E., Veronese, M. E., and Birkett, D. J. (1988) Tolbutamide hydroxylation by human liver microsomes: Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37, 1137-1144.
30. Meier, U. T., Kronbach, T., and Meyer, U. A. (1985) Assay of mephenytoin metabolism in human liver microsomes by highperformance liquid chromatography. Anal. Biochem. 151, 286-291.
31. Kronbach, T., Mathys, D., Gut, J., Catin, T., and Meyer, U. A. (1987) High-performance liquid Chromatographie assays for bufurolol l'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan o-deethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal. Biochem. 162, 24-32.
32. Peter, R., Bocker, R., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C. S. (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIEI. Chem. Res. Toxicol. 3, 566-573.
33. Sonderfan, A. J., Arlotto, M. P., Dutton, D. R., McMillen, S. K., and Parkinson, A. (1987) Regulaton of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255, 27-41.
34. Walsh, C. T. (1984) Suicide substrates, mechanism-based enzyme inactivation: recent developments, Annu. Rev. Biochem. 53, 493-535.
35. Ueng, Y. F., Kuwabara, T., Chun, Y. J., and Guengerich, F. P. (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381.
36. Vanakoski, J., Mattila, M. J., and Seppala, T. (1996) Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur. J. Clin. Pharmacol. 50, 501-508.
37. Mays, D. C., Hilliard, J. B., Wong, D. D., Chambers, M. A., Park, S. S., Gelboin, H. V., and Gerber, N. (1990) Bioactivation of 8-methoxypsoralen and irreversible inactivation of cytochrome P-450 in mouse liver microsomes: modification by monoclonal antibodies, inhibition of drug metabolism and distribution of covalent adducts. J. Pharmacol, Exp. Ther. 254, 720-731.
38. Chiba, M., Nishine, J. A., and Lin, J. H. (1995) Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754, 394, an investigational HIV protease inhibitor. J. Pharmacol. Exp. Ther. 275, 1527-1534.
39. Sahali-Sahly, Y., Balani, S. K., Lin, J. H., and Baillie, T. A. (1996) In vitro studies on the metabolic activation of the furanopyridine L-754, 394, a highly potent and selective mechanism-based inhibi-tor of cytochrome P450 3A4. Chem. Res. Toxicol. 9, 1007-1012.
40. Guengerich, F. P. (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3, 363-371.
41. Ortiz de Montellano, P. R., and Correia, M. A. (1995) Inhibition of cytochrome P450. In Cytochrome P450 - Structure, Mechanism and Biochemistry (Ortiz de Montellano, P. R., Ed.) pp 305-366, Plenum Press, New York.
42. He, K., Falick, A. M., Chen, B., Nilsson, F., and Correia, M. A. (1996) Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital. Chem. Res. Toxicol, 9, 614-622.
43. He, K., He, Y. A., Szklarz, G. D., Halpert, J. R., and Correia, M. A. (1996) Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants: partitioning between heme and protein alkylation and epoxidation. J. Biol. Chem. 271, 25864-25872.
44. Yao, K., Falick, A. M., Patel, N., and Correia, M. A. (1993) Cumene hydroperoxide- inactivation of cytochrome P450 2B1: identification of an active site heme-modified peptide. J. Biol. Chem. 268, 59-65.
45. 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry. Biochemistry 33, 3766-3771.
46. Roberts, E. S., Hopkins, N. E., Zaluzec, E. J., Gage, D. A., Alworth, W. L., and Hollenberg, P. F. (1995) Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenanthrene. Arch. Biochem. Biophys. 323, 295-302.
47. Peters, W. H. M., and Kremers, P. G. (1989) Cytochrome P450 in the intestinal mucosa of man. Biochem. Phamacol. 38, 1535-1538.